Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1995 Nov;3 Suppl 4:537S-540S.
doi: 10.1002/j.1550-8528.1995.tb00224.x.

Pharmacological and Clinical Studies of Ephedrine and Other Thermogenic Agonists

Affiliations
Free article
Review

Pharmacological and Clinical Studies of Ephedrine and Other Thermogenic Agonists

A Astrup et al. Obes Res. .
Free article

Abstract

When given as a supplement to an energy restricted diet the sympathomimetic agent ephedrine, in combination with methylxanthines such as caffeine, improves fat loss by dual actions: a central suppression of appetite and peripheral stimulation of energy expenditure covered by fat oxidation. Mean weight loss was found to be 16.6 kg after 6 months when E+C was given as an adjuvant to an efficient hypoenergetic diet, which was 3.4 kg higher than in the placebo group. An additional 24 weeks treatment with E+C prevented relapse. In the first weeks of treatment E+C offset the hypotensive effect of energy restriction and weight loss, but the effect was transient, and after 8 weeks blood pressures were indistinguishable from those of the placebo group. E+C has no adverse effect on glucose and lipid metabolism, but has been shown to prevent the decline in HDL-cholesterol caused by weight loss. In a comparative trial the weight loss produced by E+C was similar to that of dexfenfluramine. More research on sympathomimetics and methylxanthines should be carried out to identify combinations with improved efficiency and safety. Moreover, more long-term trials and studies in males are required.

Similar articles

See all similar articles

Cited by 4 articles

MeSH terms

LinkOut - more resources

Feedback